ArticleOncotarget2016
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer.Genes & genomics · 2025Article
- Article
- The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.Cellular & molecular biology letters · 2024Review
- GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer.International journal of molecular sciences · 2023Article
- Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts.Molecular oncology · 2023Article
- The Potential of hsa-mir-106b-5p as Liquid Biomarker in Prostate Cancer Patients in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- MiR-543/Numb promotes proliferation, metastasis, and stem-like cell traits of prostate cancer cells.American journal of translational research · 2021Article
- CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.The Journal of clinical investigation · 2020Article
- Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia.Journal of Cancer · 2020Article
- MicroRNA-488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3.FEBS open bio · 2019Article
- LSGSP: a novel miRNA-disease association prediction model using a Laplacian score of the graphs and space projection federated method.RSC advances · 2019Article
- Rho-Associated Protein Kinase (ROCK) Promotes Proliferation and Migration of PC-3 and DU145 Prostate Cancer Cells by Targeting LIM Kinase 1 (LIMK1) and Matrix Metalloproteinase-2 (MMP-2).Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Meeting Between Rumi and Shams in Notch Signaling; Implications for Pain Management: A Narrative Review.Anesthesiology and pain medicine · 2019Review
- Identification of biomarker microRNA-mRNA regulatory pairs for predicting the docetaxel resistance in prostate cancer.Journal of Cancer · 2019Article
- CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NADMolecular cancer research : MCR · 2018Article
- Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking.Journal of cancer research and clinical oncology · 2018Article
- Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT).BMC neurology · 2018Article
- Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma.Oncology reports · 2018Article
- Notch1 suppresses prostate cancer cell invasion via the metastasis-associated 1-KiSS-1 metastasis-suppressor pathway.Oncology letters · 2017Article
- Notch system is differentially expressed and activated in pituitary adenomas of distinct histotype, tumor cell lines and normal pituitaries.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
Adenocarcinomas of the prostate arise as multifocal heterogeneous lesions as the likely result of genetic and epigenetic alterations and deranged cell-cell communication. Notch signaling is an important form of intercellular communication with a role in growth/differentiation control and tumorigenesis. Contrasting reports exist in the literature on the role of this pathway in prostate cancer (PCa) development. We show here that i) compared to normal prostate tissue, Notch1 expression is significantly reduced in a substantial fraction of human PCas while it is unaffected or even increased in others; ii) acute Notch activation both inhibits and induces process networks associated with prostatic neoplasms; iii) down-modulation of Notch1 expression and activity in immortalized normal prostate epithelial cells increases their proliferation potential, while increased Notch1 activity in PCa cells suppresses growth and tumorigenicity through a Smad3-dependent mechanism involving p21WAF1/CIP1; iv) prostate cancer cells resistant to Notch growth inhibitory effects retain Notch1-induced upregulation of pro-oncogenic genes, like EPAS1 and CXCL6, also overexpressed in human PCas with high Notch1 levels. Taken together, these results reconcile conflicting data on the role of Notch1 in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.